Moderna announced it is scaling back investments in vaccine trials, CEO comments reported on Bloomberg TV. The company cited growing political and public resistance in the U.S. to expanded vaccine programs as the primary reason for the pullback. The move signals a strategic shift at one of the largest mRNA developers and may slow near-term trial starts and vaccine-focused R&D spend. Investors and industry watchers will watch guidance and portfolio reprioritization from Moderna for signals about funding allocation across infectious disease and oncology mRNA programs. The comments were delivered directly by Moderna's CEO in a Bloomberg TV interview, underscoring the public-policy link to private R&D strategy.